Evidence map›Paper›PMID 14634803›Full record

ArticleEuropean journal of pediatrics2003

Long-term outcome of patients with urea cycle disorders and the question of neonatal screening.

Claude Bachmann

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in European journal of pediatrics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Hyperammonemia in Inherited Metabolic Diseases.Cellular and molecular neurobiology · 2022
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques · 2013
    Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Brain imaging in urea cycle disorders.Molecular genetics and metabolism · 2010
    Review
  19. Article
  20. Neurological implications of urea cycle disorders.Journal of inherited metabolic disease · 2007
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Claude BachmannLaboratoire Central de Chimie Clinique, Centre Hospitalier Universitaire Vaudois, Bugnon 46, 1011, Lausanne, Switzerland. Claude.Bachmann@chuv.hospvd.ch
University Hospital of Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledWith regard to the principles established for neonatal population screening, the question arises whether for patients with urea cycle disorders there is an accepted treatment which really affects the disease course and prognosis as compared to the natural history of these diseases. A retrospective study of 88 patients was performed. Based on questionnaires, the survival rate and neurodevelopmental outcome of patients treated with protein restriction alone was compared to the new therapy introduced in the 1980s with added citrulline/arginine, essential amino acids for improving the amino acid composition of the restricted natural protein and benzoate. Survival of patients with neonatal presentation was improved by the extensive therapy but this mostly at the cost of an increasing number of retarded patients. Long-term outcome did not differ significantly between the two treatments. Of all patients, 56% were symptomatic within 4 days of age and 67% within the 1st week. Thus a prevention of irreversible damage by neonatal screening on blood obtained at 3-4 days of life is questionable. Whether the benefit of obtaining a rapid diagnosis, e.g. for allowing proper counselling and prospective treatment, is acceptable for the parents of prospective patients remains open. The organisation of a dense network of specialised metabolic centres with sufficient staff and resources is a prior condition for any screening programme in order to ensure the rapid diagnosis, follow-up of treatment and counselling of a cumulative number of affected chronic patients needing this support. A commitment on a long-term basis by the institutions is needed in view of the health budget restrictions.

conclusionin the short term, the goal is to detect hyperammonaemic patients as early as possible with special emphasis on sick neonates. In practice, quantitative plasma ammonia determination without delay is recommended in any newborn for whom a sepsis work-up is considered and in children who refuse feeding or vomit and show alterations of consciousness and/or neurological symptoms.

Indexed as

Amino Acid Metabolism, Inborn ErrorsAmino AcidsArginineArgininosuccinic AcidChildCitrullineDietFalse Positive ReactionsHumansHyperammonemiaInfant, NewbornIntellectual DisabilityMetabolism, Inborn ErrorsNeonatal ScreeningRetrospective StudiesTreatment OutcomeAmino AcidsArginineArgininosuccinic AcidCitrullineUrea

Identifiers

PMID14634803
OpenAlexW2013171006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.